Bayer HealthCare and Cardinal Health announced, on Dec. 18, 2014, the signing of a 15-year agreement for the contract manufacturing of Xofigo (radium Ra 223 dichloride). As part of the agreement, Cardinal Health will build a 64,000-ft 2 facility in Indianapolis, Indiana that will beOriginal Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.